A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis.

Trial Profile

A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Sep 2013 The extension trial status was changed from recruiting to completed according to the Clinicalrials.gov record. Actual patient number is 143.
    • 03 Sep 2013 The extension trial status was changed from recruiting to completed according to the Clinicalrials.gov record. Actual patient number is 143.
    • 13 Apr 2012 Planned patient number for the extension trial (NCT00670449) is now 165.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top